Company Profile and History

Company Profile

Company Name FIMECS, Inc.
Address 26-1, Muraoka-Higashi 2-Chome,
Fujisawa, Kanagawa 251-0012, JapanMap
TEL: +81-466-96-0261
Establishment Jan. 18th, 2018
CEO Katsuhiro Uto, Ph.D.
Capital 100 million yen (as of December 31, 2023)
Number of Members 4 board members and 23 employees(as of April 1, 2025)
Business Drug Discovery based on Targeted Protein Degradation

History

Month/Year Overview
  • Jan 2018Founded in Fujisawa, Kanagawa, Japan
  • Feb 2018Executed a license agreement with Takeda Pharmaceutical Co., Ltd. to use IRAK-M and others-related compounds, and the associated know-how on targeted protein degradation
  • Mar 2018A seed financing round was led by Takeda Pharmaceutical Co., Ltd. and Cosmo Bio Co., Ltd.
  • May 2018Executed a collaborative research agreement with the National Institute of Genetics on Auxin-Inducible Degron technology
  • Mar 2019“Drug Discovery Research for Acute Myeloid Leukemia Targeting Trib” was selected by the Japan Agency for Medical Research and Development (AMED) for its Cyclic Innovation for Clinical Empowerment (CiCLE) program.
  • Aug 2019Executed a collaborative research agreement with Kyoto University on drug discovery research for targeted protein degradation that target ILK
  • Oct 2019Executed a collaborative research agreement with The University of Tokyo on proteomics
  • Dec 2019A seed extension round was raised a fund from Kiichiro Nakajima
  • Feb 2020A Series A round 1st closing was led by Kyoto University Innovation Capital Co., Ltd. along with ANRI Co., Ltd.
  • Apr 2020A Series A round 2nd closing was completed by investment from UTokyo Innovation Platform Co., Ltd.
  • Jul 2021A research plan of developing and expanding RaPPIDS™ Platform was adopted grant funding “Product Commercialization Alliance (PCA)” by the New Energy and Industrial Technology Development Organization (NEDO)
  • Jan 2022A Series B round was led by Nissay Capital Co., Ltd. along with ANRI Co., Ltd., Kyoto University Innovation Capital Co., Ltd., and UTokyo Innovation Platform Co., Ltd. as the underwriters
  • Jan 2022Executed a “research collaboration agreement with option for licensing” with Astellas Pharma Inc. for targeted protein degradation
  • Mar 2024Became a wholly-owned subsidiary of RaQuallia Pharma by M&A